A groundbreaking international study has revealed a surprising truth about the oxygen levels used during resuscitation for extremely preterm infants. The TORPIDO 30/60 trial, a major undertaking across six countries, has found that starting these vulnerable newborns with a higher concentration of oxygen does not reduce the risk of death or brain injury compared to a lower-oxygen approach. This long-awaited clarity on a decades-old debate in neonatal care is a game-changer.
The TORPIDO 30/60 randomised clinical trial set out to determine if initiating resuscitation with an inspired oxygen fraction (FiO₂) of 0.6 offered any clinical advantage over 0.3 for infants born between 23 and 28 weeks' gestation. The optimal oxygen level for this critical stage has been a mystery, with valid concerns on both sides: too little oxygen risks hypoxia, while excessive oxygen may lead to oxidative injury and long-term neurodevelopmental issues.
The study involved 1641 newborns across 31 hospitals in Australia, India, Malaysia, Singapore, Spain, and the United States. A standardised approach was used, with infants randomised shortly before birth and then receiving either 0.3 or 0.6 FiO₂ initially. Oxygen levels were then adjusted based on established pulse oximetry targets during the first 10 minutes of life.
The results are eye-opening. At 36 weeks' corrected gestational age, the combined rate of death or brain injury was virtually identical between the two groups: 46.9% for infants started at FiO₂ 0.6 and 47.8% for those started at 0.3 (relative risk 0.98; 95% CI 0.89–1.09). This finding suggests that the initial choice of oxygen concentration does not significantly impact early outcomes for extremely preterm infants.
But here's where it gets controversial: the study also found that the escalation to 100% oxygen was similar between the groups (41% vs 38%), indicating that the initial oxygen choice did not significantly alter subsequent clinical management. This challenges the conventional wisdom that higher initial oxygen levels might lead to better outcomes.
So, what does this mean for future neonatal research? The researchers believe that these results provide an essential foundation for exploring more nuanced or individualised oxygen strategies. With prematurity still a leading cause of neonatal mortality worldwide, the TORPIDO 30/60 trial offers timely guidance for clinicians and highlights the importance of precision-driven approaches in the delivery room.
This study raises important questions: Should we continue to aim for higher oxygen levels during resuscitation, or is it time to explore more tailored approaches? What other factors might influence the optimal oxygen strategy for preterm infants? Share your thoughts in the comments; let's spark a discussion on this critical topic!
